Download Free Medical ANTIARRHYTHMIC DRUGS PowerPoint Presentation

ANTIARRHYTHMIC DRUGS PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pharmacology, which is titled "ANTIARRHYTHMIC DRUGS", to know about antiarrhythmic drugs.

Tags : Pharmacology, antiarrhythmic drugs

Published on : Jul 18, 2021 | Views : 1971 | Downloads : 13

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Assoc. Prof. Ivan Lambev www.medpharm-sofia.eu Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology ANTIARRHYTHMIC DRUGS (Summary)
Slide 2-

ppt slide no 2 content not found
Slide 3-

Myocardial cells maintain transmembrane ion gradients by movement of the Na+, Ca2+ and K+ through membrane channels. The resting potential of a cardiac cell is – 85 mV compared to the extracellular environment. Depolarization is initiated by a rapid influx of Na+ (phase 0). BASIC ELECTROPHYSIOLOGY
Slide 4-

Depolarization Rapid repolarization Final repolarization Plateau Resting potential Spontaneous depolarization
Slide 5-

In the AV node depolarization is due to the slower influx of calcium ions. This results in slower conduction of the impulse through the AV node than in other parts of the heart.
Slide 6-

During the period between phase 0 and the end of phase 2, the cell is refractory to the further depolarization (absolute refractory period) since the sodium channels are inactivated. During phase 3, a sufficiently large stimulus can open enough sodium channels to over- come the potassium efflux. This is the relative refractory period.
Slide 7-

Rapid repolarization Plateau Depolarization Final repolarization Spontaneous depolarization Absolute refractory period Relative refractory period Threshold potential Resting membrane potential
Slide 8-

The cardiac action potential
Slide 9-

ppt slide no 9 content not found
Slide 10-

ppt slide no 10 content not found
Slide 11-

ppt slide no 11 content not found
Slide 12-

ppt slide no 12 content not found
Slide 13-

MECHANISMS OF ARRHYTHMOGENESIS Arrhythmias can arise as the result of abnormal impulse generation or abnormal impulse conduction. The main mechanisms: RE-ENTRY (the most frequently): if an impulse arrives at an area of tissue when it is refractory to the stimulus, this impulse will be conducted by an alternative route.
Slide 14-

If the impulse again reaches the “blocked” tissue distally when it has had sufficient time to recover, the same impulse will be conducted retrogradely (re-entry). This retrograde conduction is slow, because to initiate a circuit of electrical acti- vity, the healthy tissue has to be given time to repolarize.
Slide 15-

Such a mechanism can initiate a selfperpetuating “loop” of electrical activity which acts as a pacemaker. The re-entry circuit can be localized within small a area of the myocardium or it can exist as a large circuit, for example between the atria and ventricles.
Slide 16-

AUTOMATICITY Subsidiary (or ectopic) pacemakers may develop when a site in the myocardium develops a more rapid phase 4 depolarization than the SA node, e.g. as a result of ischaemia. Spontaneous depolarization Threshold potential
Slide 17-

ANTIARRHYTHMIC DRUGS (AAD) I. AAD used in tachyarrhythmias The Vaughan William’s Classification of AAD is based on their effects on the cardiac action potential (AP).
Slide 18-

Class I (membrane stabilizers) These AAD slow the rate of raise of phase 0 of AP by inhibiting fast sodium channels. The class is subdivided according to the effects of drugs on the duration of AP. Indications: SV and ventricular arrhythmias. IA IB IC Increase the duration of AP Decrease the duration No effect on the duration
Slide 19-

IA IB IC Disopyramide Procainamide Ajmaline - weak negative inotropic effect Quinidine Lidocaine Mexiletine Phenytoin Propafenone Flecainide ADRs: Bradycardia, AV block, (–) inotropic effect, disturbances of GIT, rashes
Slide 20-

Rauwolfia serpentina Ajmaline Reserpine Cinchona succirubra Quinidine Chinine
Slide 21-

Treatment: Lidocaine, Ajmaline
Slide 22-

Ventricular fibrillation, characterized by irregular undulations without clear ventricular complexes. Treatment: Lidocaine or electrical defibrillation
Slide 23-

Ventricular flutter
Slide 24-

Class II (-adrenoceptor antagonists) Reduce the rate of spontaneous depo- larization of sinus and AV nodal tissue by indirect blockade of calcium channels. Indications: SV and ventricular arrhythmias. ( cAMP) Pindolol, Propranolol Atenolol, Esmolol
Slide 25-

Atrial flutter with a 4:1 conduction ratio. Esmolol (short action)
Slide 26-

Class III These AAD prolong the duration of the AP and increase the abso- lute refractory period. This is the result of reduced influx of K+ into the cell. Ind: SV and ventri- cular arrhythmias. Amiodarone (p.o.; i.v. inf.) t1/2 20–100 days ADRs: bradycardia, hypo/hyper thyreoidism, corneal micro-deposits under pupil, neuritis n. opticus, pulmonary fibrosis. Dronedarone (contains no iodine but has hepatotoxic effect) Sotalol, Bretylium
Slide 27-

Class IV (calcium channel antagonists) Mainly Verapamil (22% oral availability) and Diltiazem (i.v.) from calcium antagonists have specific action on the SA and AV nodes. They decrease the duration of AP. Ind: SV arrhythmias. ADRs: headache, edema, bradycardia, AV block
Slide 28-

Atrial fibrillation
Slide 29-

ppt slide no 29 content not found
Slide 30-

Adenosine inhibits AV conduction. The duration of effect is less than 60 s. used as an i.v. bolus in SV tachycardia with narrow QRS complex. ADRs: bradycardia, AV block. Other drugs used in tachyarrhythmias Digoxin reduces conduction through the AV node and is useful in the control of atrial flutter and atrial fibrillation.
Slide 31-

Atropine is given by bolus i.v. inj. in sinus brady- cardia and AV block. It blocks M2-receptors and increases conduction through the AV node. Isoprenaline is used in AV block II. AAD used in bradyarrhythmias Atropa belladonna L.
Slide 32-

Pacemaker
Slide 33-

Digitalis purpurea (foxglove) Digitalis lanata Digitoxin Digoxin Phenytoin Potassium chloride Magnesium aspartate Digoxin- specific FAB (Fragment AntiBody): Digibind® (38 mg connect 0,5 mg Digoxin) III. AAD used in Digitalis arrhythmia
Slide 34-

ppt slide no 34 content not found
Slide 35-

PROARRHYTHMIC ACTIVITY OF AAD All AAD have the potential to precipitate serious arrhythmias, particularly ventri- cular tachycardia or fibrillation. Mainly the AAD from class IA prolong the Q–T interval which predisposes to the development of a polymorphic ventricular tachycardia known as “torsades de pointes”.
Slide 36-

Polymorphic ventricular tachycardia with a twisting axis on the ECG Torsades de Pointes
Slide 37-

Treat hypokalemia if it is the precipitating factor and administer magnesium sulfate in a dose of 2–4 g i.v. initially. Magnesium is usually very effective, even in the patient with a normal magnesium level. If this fails, repeat the initial dose, but because of the danger of hypermagnesemia (depression of neuromuscular function) the patient requires close monitoring. Other therapies include overdrive pacing and isoprenaline infusion. Most (75–82%) torsade de pointes rhythms are started by a pause. Pacing at rates up to 140 bpm may prevent the ventricular pauses that allow torsade de pointes to originate. The patient with torsade who is in extremis should be treated with electrical cardioversion or defibrillation. See: http://emedicine.medscape.com/article/760667-treatment Torsades de Pointes: Treatment
Slide 38-

ppt slide no 38 content not found